Thompson Siegel & Walmsley’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$18.2M Sell
72,426
-2,076
-3% -$447K 0.33% 88
2026
Q1
$16.2M Buy
74,502
+222
+0.3% +$49.2K 0.28% 89
2025
Q4
$17M Buy
74,280
+211
+0.3% +$48.1K 0.28% 94
2025
Q3
$17.1M Buy
74,069
+37
+0% +$7.54K 0.28% 95
2025
Q2
$13.7M Buy
74,032
+577
+0.8% +$107K 0.23% 102
2025
Q1
$15.4M Buy
73,455
+169
+0.2% +$32.9K 0.26% 96
2024
Q4
$13M Sell
73,286
-53
-0.1% -$9.74K 0.2% 119
2024
Q3
$14.5M Buy
73,339
+710
+1% +$133K 0.22% 103
2024
Q2
$12.5M Buy
72,629
+39
+0.1% +$6.46K 0.2% 112
2024
Q1
$13.2M Sell
72,590
-75
-0.1% -$12.9K 0.2% 110
2023
Q4
$11.3M Sell
72,665
-40
-0.1% -$5.83K 0.18% 120
2023
Q3
$10.8M Sell
72,705
-30
-0% -$4.4K 0.18% 121
2023
Q2
$9.8M Hold
72,735
0.16% 138
2023
Q1
$11.6M Sell
72,735
-6
-0% -$917 0.19% 119
2022
Q4
$11.8M Sell
72,741
-766
-1% -$117K 0.19% 122
2022
Q3
$9.87M Sell
73,507
-23,150
-24% -$3.32M 0.17% 134
2022
Q2
$14.8M Sell
96,657
-6,444
-6% -$985K 0.24% 106
2022
Q1
$16.7M Sell
103,101
-26
-0% -$3.78K 0.24% 111
2021
Q4
$14M Buy
103,127
+17,500
+20% +$2.07M 0.19% 129
2021
Q3
$9.24M Buy
85,627
+7,125
+9% +$814K 0.13% 154
2021
Q2
$8.84M Sell
78,502
-1,432
-2% -$161K 0.12% 150
2021
Q1
$8.65M Sell
79,934
-878
-1% -$93.9K 0.12% 145
2020
Q4
$8.66M Sell
80,812
-2,433
-3% -$234K 0.14% 142
2020
Q3
$7.29M Sell
83,245
-28,942
-26% -$2.72M 0.14% 136
2020
Q2
$11M Buy
112,187
+35,956
+47% +$3.17M 0.22% 109
2020
Q1
$5.81M Buy
76,231
+25,517
+50% +$2.17M 0.14% 131
2019
Q4
$4.49M Buy
50,714
+15,491
+44% +$1.29M 0.07% 173
2019
Q3
$2.67M Buy
35,223
+3,906
+12% +$268K 0.04% 187
2019
Q2
$2.28M Buy
31,317
+828
+3% +$65.1K 0.03% 196
2019
Q1
$2.46M Sell
30,489
-19,422
-39% -$1.59M 0.03% 193
2018
Q4
$4.6M Sell
49,911
-6,000
-11% -$528K 0.07% 166
2018
Q3
$5.29M Sell
55,911
-175
-0.3% -$16.6K 0.07% 173
2018
Q2
$5.2M Buy
56,086
+550
+1% +$53.7K 0.07% 184
2018
Q1
$5.26M Sell
55,536
-4,600
-8% -$505K 0.06% 216
2017
Q4
$5.82M Buy
60,136
+1,846
+3% +$174K 0.07% 215
2017
Q3
$5.18M Sell
58,290
-10,107
-15% -$769K 0.06% 228
2017
Q2
$4.96M Hold
68,397
0.06% 237
2017
Q1
$4.46M Buy
68,397
+15,820
+30% +$995K 0.05% 254
2016
Q4
$3.29M Buy
52,577
+44,693
+567% +$2.73M 0.04% 245
2016
Q3
$497K Sell
7,884
-484
-6% -$31.3K 0.01% 341
2016
Q2
$518K Sell
8,368
-28
-0.3% -$1.71K 0.01% 324
2016
Q1
$480K Buy
8,396
+1,000
+14% +$55.7K 0.01% 320
2015
Q4
$438K Sell
7,396
-250
-3% -$14.4K 0.01% 332
2015
Q3
$416K Buy
7,646
+48
+0.6% +$3.13K 0.01% 339
2015
Q2
$511K Sell
7,598
-31
-0.4% -$2.02K 0.01% 329
2015
Q1
$447K Sell
7,629
-219
-3% -$13.2K 0.01% 336
2014
Q4
$514K Buy
7,848
+267
+4% +$16.8K 0.01% 330
2014
Q3
$438K Buy
7,581
+290
+4% +$16.1K 0.01% 329
2014
Q2
$412K Sell
7,291
-2,014
-22% -$106K 0.01% 341
2014
Q1
$478K Sell
9,305
-1,376
-13% -$69.5K 0.01% 330
2013
Q4
$564K Sell
10,681
-5,846
-35% -$287K 0.01% 315
2013
Q3
$739K Sell
16,527
-4,625
-22% -$205K 0.02% 295
2013
Q2
$874K Buy
+21,152
New +$925K 0.02% 291

Other funds holding ABBV

Thompson Siegel & Walmsley's ABBV Position: Q2 2026 in Review

Thompson Siegel & Walmsley reduced its AbbVie (ABBV) stake by 2.8% in Q2 2026, selling an estimated $447K and leaving 72,426 shares worth $18.2M. The position accounts for 0.33% of the portfolio, ranked #88.

Thompson Siegel & Walmsley first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,189 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Thompson Siegel & Walmsley held 72,426 shares of AbbVie worth $18.2M as of Q2 2026.
  • Thompson Siegel & Walmsley sold 2,076 AbbVie shares in Q2 2026, an estimated $447K.
  • AbbVie made up 0.33% of Thompson Siegel & Walmsley's portfolio in Q2 2026, its #88 holding.
  • Thompson Siegel & Walmsley first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • 4,189 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2026, filed 11 Aug 2026.